// App-Quantinova.ai

OT1-04-06 : NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) &/or surgical ablation for newly oligometastatic breast cancer

Researchers

Presenter

  • Winter KA

Principal Investigators

  • Salama JK

  • Woodward WA

  • Borges VF

  • Al-Hallaq H

  • Matuszak M

  • Jaskowiak NT

  • Milano MT

  • Bandos H

  • White JR

Medical Centers

  • University of Ohio, Columbus, OH

  • Duke University Medical Center, Durham, NC

  • University of Colorado Hospital, Aurora, CO

  • The University of Chicago Medical Center, Chicago, IL

  • UT M.D. Anderson, Houston, TX.

  • University of Michigan, Ann Arbor, MI

  • NRG Oncology Statistics and Data Management Center, Philadelphia, PA

  • University of Rochester, Rochester, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved